Centocor Ortho Biotech and FDA reminded prescribers of the risk of serious fungal infections associated with TNF-α blockers, this includes the newer Simponi (golimumab).
FDA: TNF blockers increase the risk of lymphoma and other malignancies in children and adolescents. Drugs included: etanercept –Enbrel-, infliximab –Remicade- and adalimumab –HUMIRA-
Dr. Chan explains how biologic therapy (mainly through monoclonal antibodies) is changing the present and future of autoimmune and inflammatory diseases. He illustrates some examples of autoimmune diseases such as: multiple sclerosis, asthma, treatment of rheumatoid arthritis with etanercept, and others.
Scottish Medicines Consortium accepted Adalimumab (Humira) for adolescents that do not respond to other DMARDs
An excerpt from the Drug Advice issued by the Scottish Medicines Consortium on adalimumab (Humira): adalimumab (Humira) is accepted for restricted use in NHS Scotland, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13-17 years who have an inadequate response to one or more disease-modifying anti-rheumatic drugs […]